These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9518537)

  • 21. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
    Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor.
    Trabace L; Cassano T; Loverre A; Steardo L; Cuomo V
    CNS Drug Rev; 2002; 8(1):53-69. PubMed ID: 12070526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
    Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
    Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma.
    Pruneau D; Chorny I; Benkovitz V; Artru A; Roitblat L; Shapira Y
    J Neurotrauma; 1999 Nov; 16(11):1057-65. PubMed ID: 10595822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of blood-brain barrier damage in two models of experimental head injury in the rat.
    van den Brink WA; Santos BO; Marmarou A; Avezaat CJ
    Acta Neurochir Suppl (Wien); 1994; 60():456-8. PubMed ID: 7976619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury.
    Shohami E; Bass R; Wallach D; Yamin A; Gallily R
    J Cereb Blood Flow Metab; 1996 May; 16(3):378-84. PubMed ID: 8621742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antioxidant and acetylcholinesterase response to repeated malathion exposure in rat cerebral cortex and hippocampus.
    Trevisan R; Uliano-Silva M; Pandolfo P; Franco JL; Brocardo PS; Santos AR; Farina M; Rodrigues AL; Takahashi RN; Dafre AL
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):365-9. PubMed ID: 18341513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cause of acute brain swelling after the closed head injury in rats.
    Kita H; Marmarou A
    Acta Neurochir Suppl (Wien); 1994; 60():452-5. PubMed ID: 7976618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats.
    Gurevich B; Artru AA; Lam AM; Mueller AL; Merkind V; Talmor D; Katchko L; Shapira Y
    J Neurosurg; 1998 Jun; 88(6):1066-74. PubMed ID: 9609302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
    Rösler M
    Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits.
    Goldblum D; Garweg JG; Böhnke M
    J Ocul Pharmacol Ther; 2000 Feb; 16(1):29-35. PubMed ID: 10673128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
    Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
    J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-amnesic effect of extract and alkaloid fraction from aerial parts of Peganum harmala on scopolamine-induced memory deficits in mice.
    Liu W; Zhu Y; Wang Y; Qi S; Wang Y; Ma C; Li S; Jiang B; Cheng X; Wang Z; Xuan Z; Wang C
    J Ethnopharmacol; 2017 May; 204():95-106. PubMed ID: 28442406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
    Scali C; Casamenti F; Bellucci A; Costagli C; Schmidt B; Pepeu G
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1067-80. PubMed ID: 12111444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebroprotective effect of stable nitroxide radicals in closed head injury in the rat.
    Beit-Yannai E; Zhang R; Trembovler V; Samuni A; Shohami E
    Brain Res; 1996 Apr; 717(1-2):22-8. PubMed ID: 8738249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat.
    Shohami E; Novikov M; Mechoulam R
    J Neurotrauma; 1993; 10(2):109-19. PubMed ID: 8411215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.
    Amenta F; Tayebati SK; Vitali D; Di Tullio MA
    Mech Ageing Dev; 2006 Feb; 127(2):173-9. PubMed ID: 16297435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.